Center for aktiv sundhed
Copenhagen, Copenhagen N, 2200, Denmark
NCT Number: NCT03329651
Physical activity is a first line treatment for patients with type 2 diabetes (T2D), however, the vast majority of patients with T2D do not achieve satisfying glycemic control with physical activity alone, which is why pharmacological treatment with metformin is most often initiated.
It is known that metformin and exercise both activates 5' adenosine monophosphate-activated protein kinase (AMPK) in skeletal muscle and liver, and the activation of AMPK results in many different metabolic effects, including improvements in glycemic control. Because of this similarity in mechanism of action, an interaction between metformin and exercise is plausible, but knowledge in the area is sparse. Thus, the aim of this study is to assess the effects of acute physical activity with and without concomitant metformin treatment, in order to investigate whether an interaction between the two occur.
Subjects with impaired glucose tolerance will be randomized (1:1) to metformin/placebo treatment in a double-blinded way. Following a treatment run-in period of 17 days, two experimental days (one with acute exercise and one without acute exercise), separated by one week, will be performed in each subject.
This registration concerns a sub-study of another study which has previously been registrered at ClinicalTrials.gov (Unique Protocol ID: H-17012307). The specific outcomes in this registration have not previously been registered.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Copenhagen, Copenhagen N, 2200, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily treatment with metformin tablets for 24 days according to the following scheme:
Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2
Daily treatment with placebo tablets for 24 days according to the following scheme:
Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Kristian Karstoft
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03316690
Diabetes Mellitus, Diabetes Mellitus, Type 2
Copenhagen, Copenhagen N, Denmark
View Trial DetailsNCT06964620
Diabetes Mellitus, Diabetes Mellitus, Type 2
Wuhan, Hubei, China
View Trial DetailsNCT04018105
Body Weight, Diabetes Mellitus
View Trial DetailsNCT04283201
Diabetes Mellitus, Diabetes Mellitus, Type 2
Kyiv, Ukraine
View Trial Details